{"id":675094,"date":"2023-11-03T16:50:01","date_gmt":"2023-11-03T16:50:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=675094"},"modified":"2023-11-03T16:50:01","modified_gmt":"2023-11-03T16:50:01","slug":"metastatic-castrationresistant-prostate-cancer-pipeline-analysis-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-pfizer-amgen-astellas-seagen","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/metastatic-castrationresistant-prostate-cancer-pipeline-analysis-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-pfizer-amgen-astellas-seagen_675094.html","title":{"rendered":"Metastatic Castration-Resistant Prostate Cancer Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Pfizer, Amgen, Astellas, Seagen"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Metastatic Castration-Resistant Prostate Cancer Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Pfizer, Amgen, Astellas, Seagen\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Metastatic Castration-Resistant Prostate Cancer Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Pfizer, Amgen, Astellas, Seagen\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">As per DelveInsight\u2019s assessment, globally, about 75+ key pharma and biotech companies are working on 75+ pipeline drugs in the Metastatic Castration-Resistant Prostate Cancer therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>The Metastatic Castration-Resistant Prostate Cancer therapeutics market is anticipated to grow in the coming years owing to the increasing incidence, improvement in diagnosis methodologies, incremental healthcare spending across the globe, as well as treatment of mCRPC with the accessible novel therapies in the market. The pipeline of mCRPC is very robust, and some of the key players such as Astrazeneca, Takeda, Pfizer, Merck, Amgen, Bayer, Astellas Pharma, Bristol-Myers Squibb, Orion Pharmaceuticals at the global level are involved in developing therapies for mCRPC.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&ldquo;<strong>Metastatic Castration-Resistant Prostate Cancer Pipeline Insight, 2023<\/strong>&rdquo; report by DelveInsight outlines a comprehensive assessment of the present clinical\/non-clinical development activities and growth prospects across the Metastatic Castration-Resistant Prostate Cancer Market.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Metastatic Castration-Resistant Prostate Cancer Pipeline report embraces in-depth commercial, regulatory, and Metastatic Castration-Resistant Prostate Cancer clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Metastatic Castration-Resistant Prostate Cancer drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Metastatic Castration-Resistant Prostate Cancer Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights into the emerging therapies for Metastatic Castration-Resistant Prostate Cancer treatment and the aggregate therapies developed by major pharma companies.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the different Metastatic Castration-Resistant Prostate Cancer therapies segmented into early-stage, mid-stage, and late-stage of clinical development.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It outlines the major Metastatic Castration-Resistant Prostate Cancer companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report evaluates the Metastatic Castration-Resistant Prostate Cancer drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Metastatic Castration-Resistant Prostate Cancer therapeutic market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"https:\/\/www.abnewswire.com\/uploads\/b7464850279bc88b3408facc36d236dc.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Metastatic Castration-Resistant Prostate Cancer Therapeutics Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">There are approx.<strong> 75+ key companies developing therapies for Metastatic Castration-Resistant Prostate cancer<\/strong>. Currently, <strong>Clovis Oncology<\/strong> is leading the therapeutics market with its Metastatic Castration-Resistant Prostate cancer drug candidates in the most advanced stage of clinical development.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Metastatic Castration-Resistant Prostate Cancer Companies Actively Working in the Therapeutic Market Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Accutar Biotechnology Inc<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Amgen<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Astellas Pharma\/Seagen<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">AstraZeneca<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Bayer<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Clovis Oncology<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Dizal Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Eli Lilly and Company<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Forma Therapeutics, Inc.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Hinova Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Lantern Pharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Molecular Insight Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pfizer<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Progenics Pharmaceutical<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Regeneron Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Surface Oncology<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Taiho Oncology, Inc.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Veru Healthcare<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Zenith Epigenetic<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Emerging and Marketed Metastatic Castration-Resistant Prostate Cancer Drugs Covered in the Report Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">AC0176: Accutar Biotechnology<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Capivasertib: AstraZeneca<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">FT-7051: Forma Therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">HB-300: Hookipa Pharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">HP518: Hinova Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">JANX007: Janux Therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">LAVA-1207: Lava Therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Onvansertib: Cardiff Oncology<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">PNT2002: POINT Biopharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Rucaparib: Clovis Oncology<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">SRF617: Surface Oncology<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">TmPSMA-02: Tmunity Therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">ZEN003694: Zenith Epigenetics<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many more<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Metastatic Castration-Resistant Prostate Cancer Companies Working in the Market @<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/metastatic-castration-resistant-prostate-cancer-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Analysis of Emerging Metastatic Castration-Resistant Prostate Cancer Therapies by Phases<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report covers the emerging products under different phases of clinical development like &#8211;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Late-stage products (Phase III)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Mid-stage products (Phase II)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Early-stage product (Phase I)&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pre-clinical and Discovery stage candidates<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Discontinued and inactive candidates<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Metastatic Castration-Resistant Prostate cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Oral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intravenous<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Subcutaneous<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Products have been categorized under various Molecule types such as<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Small molecule<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Cell Therapy<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Peptides<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Polymer<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Small molecule<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Gene therapy<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Mechanism of Action of the Emerging Pipeline Therapies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Proto-oncogene protein c-akt inhibitor<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Ionizing radiation emitter<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Programmed cell death-1 ligand-1 inhibitor<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Androgen receptor antagonist<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Bromodomain and extra terminal domain protein inhibitor<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Polo-like kinase 1 inhibitor<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Antibody-dependent cell cytotoxicity<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">1 Phosphatidylinositol 3 kinase inhibitor<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Androgen receptor degradation enhancer<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">P300-CBP transcription factor inhibitor<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Immunologic cytotoxicity<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn How the Metastatic Castration-Resistant Prostate Cancer Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/metastatic-castration-resistant-prostate-cancer-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Metastatic Castration-Resistant Prostate Cancer Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Metastatic Castration-Resistant Prostate Cancer &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Metastatic Castration-Resistant Prostate Cancer Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Metastatic Castration-Resistant Prostate Cancer Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Metastatic Castration-Resistant Prostate Cancer Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Metastatic Castration-Resistant Prostate Cancer Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Metastatic Castration-Resistant Prostate Cancer Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Major Metastatic Castration-Resistant Prostate Cancer Companies in the Market<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Key Products in the Metastatic Castration-Resistant Prostate Cancer Therapeutics Segment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Metastatic Castration-Resistant Prostate Cancer Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Metastatic Castration-Resistant Prostate Cancer Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Metastatic Castration-Resistant Prostate Cancer Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample PDF to Explore the Key Offerings of the Report:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/metastatic-castration-resistant-prostate-cancer-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Other Trending Healthcare Reports By DelveInsight<\/strong>&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/diverticulitis-market\">Diverticulitis Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&#8220;Diverticulitis Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Diverticulitis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Diverticulitis market.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=metastatic-castrationresistant-prostate-cancer-pipeline-analysis-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-pfizer-amgen-astellas-seagen\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=metastatic-castrationresistant-prostate-cancer-pipeline-analysis-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-pfizer-amgen-astellas-seagen\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP As per DelveInsight\u2019s assessment, globally, about 75+ key pharma and biotech companies are working on 75+ pipeline drugs in the Metastatic Castration-Resistant Prostate Cancer therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/metastatic-castrationresistant-prostate-cancer-pipeline-analysis-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-pfizer-amgen-astellas-seagen_675094.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[425,426,417,406,404],"tags":[],"class_list":["post-675094","post","type-post","status-publish","format-standard","hentry","category-Finance","category-Financial-Market","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/675094","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=675094"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/675094\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=675094"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=675094"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=675094"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}